Kodiak Sciences stock experienced a massive surge on September 28, 2026. The stock climbed 180 percent to reach $90.69 after two investigational eye disease drugs met their primary endpoints in a pivotal Phase 3 clinical trial. The DAYBREAK study focused on wet age-related macular degeneration (wAMD). It demonstrated that both drug candidates-tarcocimab tedromer, also known as Zenkuda, and tabirafusp alfa tedromer-achieved non-inferior vision gains compared to Regeneron’s blockbuster drug, Eylea.
Breakthrough Results in DAYBREAK Phase 3 Trial
The DAYBREAK trial compared the efficacy of Kodiak’s candidates against aflibercept, the active ingredient in Eylea. Eylea is currently the industry standard for treating wAMD. After one year of treatment, both Zenkuda and tabirafusp alfa tedromer matched the vision improvements seen in the control group.
A significant differentiator in the results was the dosing frequency. Using an algorithm, Kodiak reported that 54 percent of patients receiving Zenkuda maintained a 24-week dosing schedule through the first year. In contrast, patients receiving aflibercept required a more frequent eight-week dosing interval. This extended dosing interval represents a major advantage for patient convenience and the long-term management of retinal diseases.
Regulatory Path and Market Expansion
Following the successful readout, Kodiak Sciences announced plans to file for FDA approval of Zenkuda in the fourth quarter of 2026. The company will submit a multi-indication Biologics License Application (BLA) that leverages data from five different Phase 3 studies. These studies cover a broad spectrum of retinal conditions, including:
- Wet age-related macular degeneration (wAMD)
- Diabetic retinopathy
- Retinal vein occlusion
If approved, Zenkuda will mark Kodiak’s first commercial product. The company targets a global market for retinal vascular diseases estimated at approximately $15 billion.
Expert Analysis and Safety Profile
Dr. Charles Wykoff, a surgical retina specialist at Houston Methodist Hospital, expressed optimism regarding the clinical profile of the new drug. “The Zenkuda results exceeded my expectations, delivering the clinical profile retina specialists are seeking: rapid vision and anatomic improvements comparable to aflibercept during loading, followed by meaningfully longer intervals between treatment for a majority of patients, while maintaining optimal fluid control,” Wykoff stated.
Regarding safety, Kodiak reported a favorable profile for the candidates. The company noted a numerically lower rate of cataracts compared to the aflibercept group. This development is significant because the development of tarcocimab was temporarily halted in 2023 due to an unexpected increase in cataract cases before being successfully restarted.
Competitive Landscape and Challenges
While the stock surge reflects investor enthusiasm, Kodiak faces a competitive landscape. The company must contend with several established players and emerging threats:
| Competitor | Product/Type | Market Position |
|---|---|---|
| Regeneron | Eylea (Aflibercept) | Current standard of care |
| Roche | Vabysmo | Branded rival |
| Biocon | Yesafili | Biosimilar competitor |
Additionally, with patents on aflibercept having expired, the market sees increased pressure from lower-cost biosimilars. This makes Zenkuda’s unique dosing advantages critical for market penetration.
Frequently Asked Questions
What is Zenkuda?
Zenkuda (tarcocimab tedromer) is an investigational anti-VEGF antibody biopolymer conjugate developed by Kodiak Sciences to treat eye diseases like wet age-related macular degeneration.
How does Zenkuda compare to Eylea?
In the Phase 3 DAYBREAK trial, Zenkuda demonstrated non-inferior vision gains compared to Eylea. A key advantage was that 54% of Zenkuda patients could maintain a 24-week dosing schedule, whereas Eylea patients required treatment every eight weeks.
When will Zenkuda be available for use?
Kodiak Sciences plans to file for FDA approval in the fourth quarter of 2026. Availability depends on the subsequent regulatory review and approval process.
What conditions will Zenkuda treat?
Kodiak is seeking approval for multiple indications, including wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion.
Why did Kodiak Sciences stock surge?
The stock surged because the company’s Phase 3 clinical trial results proved that its new eye disease drugs are as effective as the current market leader, Eylea, while offering potentially less frequent dosing.
